Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer

Suriyan Ponnusamy, Christopher C. Coss, Thirumagal Thiyagarajan, Kate Watts, Dong Jin Hwang, Yali He, Luke A. Selth, Iain J. McEwan, Charles B. Duke, Jayaprakash Pagadala, Geetika Singh, Robert Wake, Christopher Ledbetter, Wayne D. Tilley, Tudor Moldoveanu, James T. Dalton, Duane Miller, Ramesh Narayanan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Androgen receptor (AR) mediates the growth of prostate cancer throughout its course of development, including in abnormal splice variants (AR-SV)-driven advanced stage castration-resistant disease. AR stabilization by androgens makes it distinct from other steroid receptors, which are typically ubi-quitinated and degraded by proteasomes after ligand binding. Thus, targeting AR in advanced prostate cancer requires the development of agents that can sustainably degrade variant isoforms for effective therapy. Here we report the discovery and characterization of potent selective AR degraders (SARD) that markedly reduce the activity of wild-type and splice variant isoforms of AR at submicromolar doses. Three SARDs (UT-69, UT-155, and (R)-UT-155) bind the amino-terminal transcriptional activation domain AF-1, which has not been targeted for degradation previously, with two of these SARD (UT-69 and UT-155) also binding the carboxy-terminal ligand binding domain. Despite different mechanisms of action, all three SARDs degraded wild-type AR and inhibited AR function, exhibiting greater inhibitory potency than the approved AR antagonists. Collectively, our results introduce a new candidate class of next-generation therapeutics to manage advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)6282-6298
Number of pages17
JournalCancer Research
Volume77
Issue number22
DOIs
StatePublished - Nov 15 2017

Fingerprint

Castration
Androgen Receptors
Prostatic Neoplasms
Protein Isoforms
Androgen Receptor Antagonists
Ligands
Steroid Receptors
Proteasome Endopeptidase Complex
Transcriptional Activation
Androgens
Therapeutics
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer. / Ponnusamy, Suriyan; Coss, Christopher C.; Thiyagarajan, Thirumagal; Watts, Kate; Hwang, Dong Jin; He, Yali; Selth, Luke A.; McEwan, Iain J.; Duke, Charles B.; Pagadala, Jayaprakash; Singh, Geetika; Wake, Robert; Ledbetter, Christopher; Tilley, Wayne D.; Moldoveanu, Tudor; Dalton, James T.; Miller, Duane; Narayanan, Ramesh.

In: Cancer Research, Vol. 77, No. 22, 15.11.2017, p. 6282-6298.

Research output: Contribution to journalArticle

Ponnusamy, S, Coss, CC, Thiyagarajan, T, Watts, K, Hwang, DJ, He, Y, Selth, LA, McEwan, IJ, Duke, CB, Pagadala, J, Singh, G, Wake, R, Ledbetter, C, Tilley, WD, Moldoveanu, T, Dalton, JT, Miller, D & Narayanan, R 2017, 'Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer', Cancer Research, vol. 77, no. 22, pp. 6282-6298. https://doi.org/10.1158/0008-5472.CAN-17-0976
Ponnusamy, Suriyan ; Coss, Christopher C. ; Thiyagarajan, Thirumagal ; Watts, Kate ; Hwang, Dong Jin ; He, Yali ; Selth, Luke A. ; McEwan, Iain J. ; Duke, Charles B. ; Pagadala, Jayaprakash ; Singh, Geetika ; Wake, Robert ; Ledbetter, Christopher ; Tilley, Wayne D. ; Moldoveanu, Tudor ; Dalton, James T. ; Miller, Duane ; Narayanan, Ramesh. / Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer. In: Cancer Research. 2017 ; Vol. 77, No. 22. pp. 6282-6298.
@article{8f2492eb85e7415288107a31539cbb01,
title = "Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer",
abstract = "Androgen receptor (AR) mediates the growth of prostate cancer throughout its course of development, including in abnormal splice variants (AR-SV)-driven advanced stage castration-resistant disease. AR stabilization by androgens makes it distinct from other steroid receptors, which are typically ubi-quitinated and degraded by proteasomes after ligand binding. Thus, targeting AR in advanced prostate cancer requires the development of agents that can sustainably degrade variant isoforms for effective therapy. Here we report the discovery and characterization of potent selective AR degraders (SARD) that markedly reduce the activity of wild-type and splice variant isoforms of AR at submicromolar doses. Three SARDs (UT-69, UT-155, and (R)-UT-155) bind the amino-terminal transcriptional activation domain AF-1, which has not been targeted for degradation previously, with two of these SARD (UT-69 and UT-155) also binding the carboxy-terminal ligand binding domain. Despite different mechanisms of action, all three SARDs degraded wild-type AR and inhibited AR function, exhibiting greater inhibitory potency than the approved AR antagonists. Collectively, our results introduce a new candidate class of next-generation therapeutics to manage advanced prostate cancer.",
author = "Suriyan Ponnusamy and Coss, {Christopher C.} and Thirumagal Thiyagarajan and Kate Watts and Hwang, {Dong Jin} and Yali He and Selth, {Luke A.} and McEwan, {Iain J.} and Duke, {Charles B.} and Jayaprakash Pagadala and Geetika Singh and Robert Wake and Christopher Ledbetter and Tilley, {Wayne D.} and Tudor Moldoveanu and Dalton, {James T.} and Duane Miller and Ramesh Narayanan",
year = "2017",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-17-0976",
language = "English (US)",
volume = "77",
pages = "6282--6298",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer

AU - Ponnusamy, Suriyan

AU - Coss, Christopher C.

AU - Thiyagarajan, Thirumagal

AU - Watts, Kate

AU - Hwang, Dong Jin

AU - He, Yali

AU - Selth, Luke A.

AU - McEwan, Iain J.

AU - Duke, Charles B.

AU - Pagadala, Jayaprakash

AU - Singh, Geetika

AU - Wake, Robert

AU - Ledbetter, Christopher

AU - Tilley, Wayne D.

AU - Moldoveanu, Tudor

AU - Dalton, James T.

AU - Miller, Duane

AU - Narayanan, Ramesh

PY - 2017/11/15

Y1 - 2017/11/15

N2 - Androgen receptor (AR) mediates the growth of prostate cancer throughout its course of development, including in abnormal splice variants (AR-SV)-driven advanced stage castration-resistant disease. AR stabilization by androgens makes it distinct from other steroid receptors, which are typically ubi-quitinated and degraded by proteasomes after ligand binding. Thus, targeting AR in advanced prostate cancer requires the development of agents that can sustainably degrade variant isoforms for effective therapy. Here we report the discovery and characterization of potent selective AR degraders (SARD) that markedly reduce the activity of wild-type and splice variant isoforms of AR at submicromolar doses. Three SARDs (UT-69, UT-155, and (R)-UT-155) bind the amino-terminal transcriptional activation domain AF-1, which has not been targeted for degradation previously, with two of these SARD (UT-69 and UT-155) also binding the carboxy-terminal ligand binding domain. Despite different mechanisms of action, all three SARDs degraded wild-type AR and inhibited AR function, exhibiting greater inhibitory potency than the approved AR antagonists. Collectively, our results introduce a new candidate class of next-generation therapeutics to manage advanced prostate cancer.

AB - Androgen receptor (AR) mediates the growth of prostate cancer throughout its course of development, including in abnormal splice variants (AR-SV)-driven advanced stage castration-resistant disease. AR stabilization by androgens makes it distinct from other steroid receptors, which are typically ubi-quitinated and degraded by proteasomes after ligand binding. Thus, targeting AR in advanced prostate cancer requires the development of agents that can sustainably degrade variant isoforms for effective therapy. Here we report the discovery and characterization of potent selective AR degraders (SARD) that markedly reduce the activity of wild-type and splice variant isoforms of AR at submicromolar doses. Three SARDs (UT-69, UT-155, and (R)-UT-155) bind the amino-terminal transcriptional activation domain AF-1, which has not been targeted for degradation previously, with two of these SARD (UT-69 and UT-155) also binding the carboxy-terminal ligand binding domain. Despite different mechanisms of action, all three SARDs degraded wild-type AR and inhibited AR function, exhibiting greater inhibitory potency than the approved AR antagonists. Collectively, our results introduce a new candidate class of next-generation therapeutics to manage advanced prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85033771016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033771016&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-0976

DO - 10.1158/0008-5472.CAN-17-0976

M3 - Article

VL - 77

SP - 6282

EP - 6298

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 22

ER -